<DOC>
	<DOCNO>NCT02777814</DOCNO>
	<brief_summary>There report whether patient colorectal cancer also inactive Hepatitis B Carriers receive Prophylactic Use preemptive Use Anti-viral Drug Entecavir . This open , randomize control clinical trial aim compare impact prophylactic use preemptive use anti-viral drug Entecavir outcomes patient colorectal cancer also inactive hepatitis B carrier chemotherapy subsequent follow-up .</brief_summary>
	<brief_title>Prophylactic Preemptive Entecavir Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Patients age 18 75 2 . Patient histologyproven colorectal adenocarcinoma . 3 . Patients Eastern Cooperative Oncology Group performance status ( ECOG ) 01 4 . Patients plan least 4 cycle cytotoxic chemotherapy ( either part curative therapy palliative therapy ) 5 . Patients least 6 month ' life expectancy date recruitment 6 . Patients positive Hepatitis B Surfaceantigen ( HBsAg ) 7 . Patients normal liver function test include alanine aminotransferase ( ALT ) , aspartate aminotransferase alkaline ( AST ) , phosphatase ( ALP ) , gamma glutamyltranspeptidase ( GGT ) , bilirubin 8 . Patients negative HBVDNA 9 . Patients known history radiological &amp; /or histological diagnosis chronic active hepatitis cirrhosis cause , history prior hepatitis B reactivation , prior chronic therapy HBV within 6 month 10 . Patients evidence autoimmune hepatitis , hepatitis C D virus infection , HIV infection radiological evidence liver metastasis 11. adequate bone marrow , hepatic , renal function within 14 day recruitment 12. patient sign inform consent 13 . Patients good compliance chemotherapy followups 1 . Patients plan radiation radionuclide therapy 2 . Pregnant female patient 3 . Patients history psychiatric drug abuse ca n't quit mental disorder 4 . Patients immunodeficiency , congenital acquire immunodeficiency , transplantation history 5 . According investigator ' judgment , patient concomitant disease seriously harm patient ' safety completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Entecavir</keyword>
	<keyword>Hepatitis B Carrier</keyword>
</DOC>